Soliris

$17.00

Description

Soliris is a first-in-class terminal complement inhibitor discovered, developed, and commercialized. Soliris works by selectively inhibiting activation of specific proteins in the complement system (C5a and C5b), which play a role in the treatment of multiple rare diseases.

Reviews

There are no reviews yet.

Be the first to review “Soliris”

Your email address will not be published. Required fields are marked *